8月13日，医疗器械行业上涨0.09%，今日主力资金流出7.93亿元，成分股40只上涨，57只下跌。 主力资金净流出居前的分别为安必平（1959.61万元）、美好医疗（1874.35万元）、ST凯利（1873.81万 元）、超研股份（1867.59万元）、万孚生物（1671.12万元）。 序号代码名称最新价涨跌幅主力净流入主力净占比1688108赛诺医疗29.517.481.19亿元3.43%2300289利 德曼11.334.916644.74万元4.8%3870199倍益康47.346.533963.65万元10.19%4688068热景生物 232.611.413236.01万元5.98%5300238冠昊生物18.283.753164.59万元8.39%6688277天智航- U19.232.181872.46万元7.35%7002022科华生物7.742.111469.12万元6.4%8603987康德莱9.340.971360.65 万元4.53%9688271联影医疗131.04-0.11182.31万元2.08%10300653正海生物22.58-0.881148.09万元8.24% 来源：金 ...

为规范公司募集资金的管理和使用，保护中小投资者的权益，根据《深圳证 券交易所创业板股票上市规则》《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》等有关法律法规和公司《募集资金使用管理制 度》的规定，经公司第二届董事会第六次会议审议通过《关于设立募集资金专户 并授权签订募集资金三方监管协议的议案》，公司设立了募集资金专项账户。 2025 年 2 月 11 日，公司会同保荐机构中国银河证券股份有限公司分别与广 发银行股份有限公司汕头分行、交通银行股份有限公司汕头分行、创兴银行有限 公司汕头分行签署了《募集资金专户存储三方监管协议》，对募集资金的存放和 使用进行专户管理。具体内容详见公司披露于巨潮资讯网的《关于签订募集资金 证券代码：301602 证券简称：超研股份 公告编号：2025-033 汕头市超声仪器研究所股份有限公司 关于签订募集资金专户存储三方监管协议之补充协议的公 告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 一、募集资金基本情况 经中国证券监督管理委员会《关于同意汕头市超声仪器研究所股份有限公司 首次公开发行股票注册的 ...

Group 1 - The core viewpoint of the news is that Chao Yan Co., Ltd. (超研股份) has shown significant financial growth in its latest quarterly report, with notable increases in revenue and net profit [1] - As of August 11, 2025, Chao Yan Co., Ltd. closed at 28.68 yuan, reflecting a 5.13% increase, with a trading volume of 114,500 hands and a transaction amount of 326 million yuan [1] - The company's total operating revenue for the first quarter of 2025 was 98.43 million yuan, representing a year-on-year growth of 28.69%, while the net profit attributable to shareholders was 39.32 million yuan, up 47.70% year-on-year [1] Group 2 - Chao Yan Co., Ltd. has a current liquidity ratio of 12.605 and a quick ratio of 11.524, indicating strong short-term financial health [1] - The company has a low debt-to-asset ratio of 8.39%, suggesting a conservative approach to leveraging [1] - The company has made investments in 12 enterprises and has participated in 705 bidding projects, showcasing its active engagement in the market [2]

Group 1 - The core viewpoint of the articles highlights the performance and valuation of Chao Yan Co., Ltd. in the medical device industry, noting its recent stock price increase and market position [1] - As of August 11, Chao Yan Co., Ltd. closed at 28.68 yuan, up 5.13%, with a rolling PE ratio of 77.61, marking a new low in 114 days, and a total market capitalization of 12.284 billion yuan [1] - The average PE ratio for the medical device industry is 56.56, with a median of 39.76, placing Chao Yan Co., Ltd. at the 97th position in the industry ranking [1] Group 2 - As of the first quarter of 2025, 118 institutions hold shares in Chao Yan Co., Ltd., with a total holding of 71,100 shares valued at 0.02 billion yuan [1] - The main business of Chao Yan Co., Ltd. includes the research, production, and sales of medical imaging equipment and industrial non-destructive testing equipment, with key products being industrial ultrasound, medical ultrasound, X-ray, and accessories [1] - The company has established a strong market presence and customer base, with its industrial ultrasound non-destructive testing products recognized as a Guangdong provincial brand [1] - In 2022, Chao Yan Co., Ltd. received the second prize for the National Defense Technology Invention Award from the Ministry of Industry and Information Technology for its project on new technology for high-precision non-destructive testing of complex large components [1] Group 3 - The latest performance report for the first quarter of 2025 shows that Chao Yan Co., Ltd. achieved operating revenue of 98.4324 million yuan, a year-on-year increase of 28.69%, and a net profit of 39.3220 million yuan, a year-on-year increase of 47.70%, with a gross profit margin of 73.83% [1]

8月11日午后，医疗板块再发力，A股最大医疗ETF（512170）放量冲击2%，成交超5亿元，场内持续溢价交易，显示买盘资金旺盛。 成份股方面，医疗器械概念股领涨，南微医学飙升近11%，心脉医疗涨近8%。CXO概念亦活跃，昭衍新药涨超3%，泰格医药涨超2%。 | | | 多日 1分 5分 15分 3047 | 6047 19 | | Ed | 盘前盘后 叠加 九转 画线 工具 谷 | 12 > | 医疗ETF O | | 512170 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | 512170[医疗ETF] 14:04 价 0.373 涨跌 0.007(1.91%) | | | 均价 0.370 成交量 3791 | OPV 9196 | | | +0.007 +1.91% | | | | | | 512170场内持续溢价 | | | | 0.376 | | 通融/● + | | | | | | | | | | SSE CNY 14:04:25 不用用 | | | | 0.371 | | | | Cl ...

Core Viewpoint - Shantou City and Shanghai Securities News signed a strategic cooperation agreement to build a new ecosystem of "capital + technology innovation + industry" [4][5] Group 1: Strategic Cooperation - The agreement aims for resource sharing, complementary advantages, and deep cooperation to achieve innovation and upgrading in industries through media platforms, capital empowerment, and technology innovation leadership [4][5] - This cooperation represents a successful exploration of the "media + city" model, enhancing mutual engagement [5] Group 2: Shantou's Economic Development - Shantou, one of China's first special economic zones, is focusing on an "industrial city, strong industry" strategy, establishing a "three new, two special, one big" industrial structure [5] - The three emerging industries include new energy, new materials, and next-generation electronic information, while the two traditional industries are textile and apparel, and toy creativity, alongside the major health industry [5] Group 3: Health Industry Conference - The first Shantou Health Industry Innovation Development Conference and Health Product Expo was held, gathering over a thousand experts and representatives from various sectors to discuss Shantou's health development [5] - Shantou's health industry is supported by historical resources and over 160 health enterprises, including leading companies like Tai En Kang and Yue Wan Nian Qing [5] Group 4: Role of Shanghai Securities News - Shanghai Securities News will regularly organize interactions between listed companies, strong enterprises, and financial investment institutions in Shantou to enhance information exchange and industry connections [6] - The media outlet aims to leverage its professional advantages to highlight Shantou's advanced experiences in technology innovation, industry innovation, and financial services [6][7]

天眼查商业履历信息显示，汕头市超声仪器研究所股份有限公司，成立于1982年，位于汕头市，是一家 以从事其他制造业为主的企业。企业注册资本42832.9638万人民币，实缴资本36408.0192万人民币。公 司法定代表人为李德来。 通过天眼查大数据分析，汕头市超声仪器研究所股份有限公司共对外投资了12家企业，参与招投标项目 705次，知识产权方面有商标信息20条，专利信息239条，此外企业还拥有行政许可122个。 超研股份最新一期业绩显示，截至2025一季报，公司营业总收入9843.24万元、同比增长28.69%，归属 净利润3932.20万元，同比增长47.70%，扣非净利润3695.85万元，同比增长58.78%，流动比率12.605、 速动比率11.524、资产负债率8.39%。 金融界消息 截至2025年8月8日收盘，超研股份（301602）报收于27.28元，下跌2.57%，换手率 21.35%，成交量12.46万手，成交金额3.49亿元。 资金流向方面，今日主力资金净流出1324.70万元，占比成交额3.8%。其中，超大单净流入495.44万 元、占成交额1.42%，大单净流出1820.14万元、 ...

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Chao Yan Co., Ltd. in the medical device industry, indicating a high valuation compared to industry averages [1][2] - As of August 8, Chao Yan Co., Ltd. closed at 27.28 yuan, with a rolling PE ratio of 73.83, significantly higher than the industry average of 55.70 [1][2] - The company has a total market capitalization of 11.685 billion yuan, ranking 95th in the medical device industry based on PE ratio [1][2] Group 2 - Chao Yan Co., Ltd. reported a revenue of 98.43 million yuan for Q1 2025, representing a year-on-year increase of 28.69% [1] - The net profit for the same period was 39.32 million yuan, showing a year-on-year growth of 47.70%, with a gross profit margin of 73.83% [1] - The company specializes in the research, production, and sales of medical imaging equipment and industrial non-destructive testing equipment, with a strong market presence and stable customer base [1]

Group 1 - The total salary scale of CFOs in A-share listed companies reached 4.27 billion yuan in 2024, with an average annual salary of 814,800 yuan [1] - In the medical device sector, the average annual salary of CFOs is 1.0652 million yuan, with 31% earning below 500,000 yuan, 43% between 500,000 and 1 million yuan, 20% between 1 million and 2 million yuan, and 6% above 2 million yuan [2] - The age distribution of CFOs shows that 54% are aged between 40 and 50, 35% are over 50, and 11% are 40 or younger, with the youngest being 30 years old and the oldest being 65 years old [1] Group 2 - The top three highest-paid CFOs in the medical device sector are Zhao Yun from Mindray Medical with 8.4134 million yuan, Liu Lihua from Yuyue Medical with 4.3136 million yuan, and Jing Xiaoqian from Wandong Medical with 1.6412 million yuan [2] - The CFO with the largest salary decrease in 2024 is Zhang Qiu from Kangtong Medical, with a year-on-year decrease of 31.23%, while Xu Ning from Mcland saw the largest increase at 165.59% [2] - The educational background of CFOs shows that 71% hold a bachelor's degree, 23% a master's degree, and only 3% hold a doctoral degree, with only one CFO having a PhD [1]

从CFO的学历分布看，拥有大专、本科、硕士、博士学历的CFO占比分别为3%、71%、23%、3%。其 中，获得博士学历的CFO仅一人，为阳普医疗的闫红玉。 专题：专题|2024年度A股CFO数据报告：美的集团钟铮年薪946万，比亚迪周亚琳896万 从薪酬分布看，A股医疗设备公司CFO年薪平均值为106.52万元。经统计，处于50万以下、50万-100 万、100万-200万、200万以上各区间的人数占比分别为31%、43%、20%、6%。 作为上市公司核心管理层关键成员，财务总监CFO的地位与作用至关重要。新浪财经《2024年度A股 CFO数据报告》显示，2024年A股上市公司财务总监CFO群体薪酬规模合计达42.70亿元，平均年薪为 81.48万元。 分行业来看，统计数据显示，剔除2024年时任CFO已离任的公司后，A股共有35家上市医疗设备公司， 其聘任总体情况如下（部分统计口径剔除无效数据）。 从CFO的年龄分布来看，40岁-50岁CFO是市场的中坚力量，占比共计达到54%；50岁以上的CFO占比 为35%；40岁及以下CFO群体占比为11%。其中，目前仍任职的最年轻的上市公司CFO年龄30岁，为博 迅 ...